Recursion, Annual report and Fourth Quarter
Digest more
Recursion Pharmaceuticals (RXRX) stock surged after the company significantly beat Street forecasts with its Q4 2025 results.
Recursion Pharmaceuticals (NasdaqGS:RXRX) reports positive clinical proof of concept for REC-4881 in familial adenomatous polyposis. The company records milestone progress across its collaborations ...
Shares of Recursion Pharmaceuticals RXRX are surging Wednesday following a robust earnings report released before the bell.
Recursion Pharmaceuticals shares were 11% higher, at $3.90, after the company reported fourth-quarter revenue that was higher than last year, and a loss that was narrower than last year's.
Guidance extended from year-end 2027 to early 2028, with operating expense reduction targets reiterated and achieved at a greater scale (now 35% year-over-year, 10% below guidance). Strategic focus ...
Nvidia disclosed in a filing on Tuesday that it no longer held shares in Applied Digital, drug-discovery company Recursion ...
Nvidia sold its entire 7.71M share stake as ARK Invest bought 1.25M shares; RXRX swung 14% before closing 2% higher Wednesday.
Earnings ESP of RXRX: Recursion Pharmaceuticals has an Earnings ESP of 0.00% as the Most Accurate Estimate and the Zacks ...
Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will be featured in HighRes’ Lightning Talk at the NVIDIA GTC AI ...
Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the most promising penny stocks under $5 to buy. On February 25, Recursion Pharmaceuticals reported its financial results for Q4 and the full ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results